Aardvark investors given Oct. 13 deadline in securities class action
AI Summary- Hagens Berman notified Aardvark investors about a pending securities class action lawsuit.
- Aardvark shares fell over 56% after its February 27 trial-pause announcement.
- FDA placed a full clinical hold on ARD-101 studies on May 14, 2026.